



## FOR IMMEDIATE RELEASE

CONTACT:  
Kelly Sladek  
SCORR Marketing  
308.237.5567  
kelly@scorrmktg.com

### Camargo Experts to Host July Webcasts

**(Cincinnati, OH; June 29, 2010)** – [Camargo Pharmaceutical Services](#)' experts, Ken Phelps, president and CEO, William Stoltman, J.D., senior director, regulatory affairs and quality assurance, and Lynn Gold, Ph.D, vice president of CMC services, will be presenting the "505(b)(2) Regulatory Alternative and the Quality Modules" webcast, sponsored by the Regulatory Affairs Professionals Society (RAPS), and the "Leveraging the Unapproved Drug Initiative" webinar, sponsored by Elsevier. Camargo is a full-service clinical research organization (CRO) specializing in end-to-end drug development through the 505(b)(2) process.

The ["505\(b\)\(2\) Regulatory Alternative and the Quality Modules"](#) webcast will take place on Wednesday, July 7, 2010, from 12:00 pm – 1:30 pm (EDT). Through this webcast, Camargo experts will provide an overview of the construction of the quality modules 2 and 3 for the Common Technical Document (CTD). They will discuss the impact of the 505(b)(2) requirements on the quality development pathway as well as how to identify critical quality components and preparation of the quality module of the submission.

The ["Leveraging the Unapproved Drug Initiative"](#) webinar is scheduled for Thursday, July 8, 2010, from 1:00 pm – 2:30 pm (EDT). President and CEO Ken Phelps will discuss how the Unapproved Drug Initiative has proved to have a major influence on the drug approval landscape. Phelps will demonstrate how to obtain approval for "new" drugs and ensure compliance to gain the upper hand on competition. He will also cover what the Food and Drug Administration (FDA) wants to see, as well as the red flags to be cautious of.

"We are very pleased to have the opportunity to present our findings," stated Phelps. "We encourage those interested in these topics to join us for thorough discussion and tips based on our specialized experience in the 505(b)(2) and drug approval arena."

Recaps of Camargo's webcasts and presentations can be found on their [blog](#), as well as insights to current industry topics and changes.

***About Camargo Pharmaceutical Services***

Camargo Pharmaceutical Services is a full-service CRO for the continuum of drug development. With more than 150 FDA approvals, Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulation and testing the drug product, conducting clinical studies and FDA application submissions. Connect with Camargo on [LinkedIn](#) or visit [www.camargopharma.com](http://www.camargopharma.com) for more information.

###